Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up
Spector, Nelson, Leber, Brian, Lipton, Jeffrey Howard, De Souza, Carmino, Moiraghi, Beatriz, Steegmann, Juan Luis, Schwarer, Anthony P., Cervantes, Francisco, Hughes, Timothy P., Purkayastha, Das, Collins, LaTonya R, Szczudlo, Tomasz K., Rea, Delphine
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up
Lipton, Jeffrey Howard, Hughes, Timothy P., Leber, Brian, De Souza, Carmino, Dorlhiac-Llacer, Pedro E, Steegmann, Juan Luis, Guerci-Bresler, Agnes, Schwarer, Anthony P., Cervantes, Francisco, Reynolds, John, Collins, LaTonya R, Szczudlo, Tomasz K., Spector, Nelson
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article